Results 171 to 180 of about 39,275 (210)
Some of the next articles are maybe not open access.
Effect of GLP-1 receptor agonists on body composition
Current Opinion in Endocrinology, Diabetes & ObesityPurpose of review Obesity is present in up to 85% of individuals with type 2 diabetes mellitus (T2DM) and poses a major therapeutic challenge. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for T2DM, are now widely used for obesity management and increasingly recognized for their ...
Akhila, Bhandarkar +2 more
openaire +2 more sources
Neoadjuvant GLP-1 Receptor Agonists in Sleep Surgery
JAMA Otolaryngology–Head & Neck SurgeryThis Viewpoint examines the potential role of neoadjuvant and adjuvant glucagon-like peptide–1 (GLP-1) receptor agonist therapy in improving surgical outcomes for patients with obstructive sleep apnea and obesity.
Ryan Chin Taw, Cheong, Kenny Peter, Pang
openaire +2 more sources
Medicina Clínica (English Edition)
Obesity represents a global public health challenge, with specific characteristics and needs in adolescent and elderly populations. GLP-1 (glucagon-like peptide-1) receptor agonists such as liraglutide and semaglutide, as well as the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor co-agonist tirzepatide, have emerged as promising ...
openaire +2 more sources
Obesity represents a global public health challenge, with specific characteristics and needs in adolescent and elderly populations. GLP-1 (glucagon-like peptide-1) receptor agonists such as liraglutide and semaglutide, as well as the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor co-agonist tirzepatide, have emerged as promising ...
openaire +2 more sources
GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
New England Journal of Medicine, 2023Sean, Wharton, Manige, Konig
openaire +4 more sources